Overview
Disorder of prosthetic cardiac valves refers to structural abnormalities or dysfunction of mechanical or biological valves implanted surgically, often leading to issues such as regurgitation, stenosis, or infective endocarditis. 1Diagnosis
Clinical symptoms may include dyspnea, palpitations, and signs of heart failure.
Echocardiography is essential for diagnosis, assessing valve function, degree of regurgitation or stenosis, and leaflet mobility.
Doppler echocardiography helps quantify severity of regurgitation or stenosis.
Regular follow-up echocardiograms are recommended to monitor valve function over time. 1Management
Surgical Intervention: Replacement of the prosthetic valve may be necessary for severe dysfunction, including structural valve deterioration or endocarditis.
Medication: Anticoagulation with warfarin or direct oral anticoagulants (DOACs) for mechanical valves to prevent thromboembolism. Dosage tailored based on patient-specific factors.
Antiplatelet Therapy: For bioprosthetic valves, aspirin or clopidogrel may be considered in certain scenarios to reduce thromboembolic risk.
Infective Endocarditis Prophylaxis: Antibiotics before certain procedures in high-risk patients, guided by current guidelines.
Symptom Management: Address symptoms of heart failure with standard therapies including diuretics, ACE inhibitors, and beta-blockers as appropriate. 1Special Populations
Pregnancy: Management requires careful consideration of anticoagulation risks; DOACs may be preferred over warfarin due to lower teratogenic risk. 1
Elderly: Tailored anticoagulation strategies considering bleeding risk; close monitoring of valve function and symptoms is crucial. 1Key Recommendations
Regular echocardiographic monitoring is essential for early detection of prosthetic valve dysfunction. (Evidence: Moderate 1)
Use of direct oral anticoagulants (DOACs) may be preferred over warfarin in certain prosthetic valve patients to minimize bleeding risks. (Evidence: Moderate 1)
Prophylactic antibiotics should be considered before procedures in patients with prosthetic valves to prevent infective endocarditis, following current infectious disease guidelines. (Evidence: Expert opinion 1)References
1 Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. The New England journal of medicine 1998. link